Across dozens of clinical trials in metastatic castration-resistant prostate cancer (mCRPC) that have randomized an experimental agent against the chemotherapy docetaxel, Rucaparib is the first and only one to demonstrate a statistically significant improvement, highlighting the difficulty of improving on this standard of care.
The trial allowed over 75% of patients in the control group to receive Rucaparib after their cancer progressed. While ethical, this high crossover rate effectively turned the study into an "upfront vs. delayed PARP inhibitor" comparison, which is the primary reason no significant overall survival difference was observed.
Experts advise using PARP inhibitors at the earliest opportunity for patients with BRCA mutations. As prostate cancer advances, it develops additional drivers of disease and intrinsic resistance, which can render targeted therapies like PARP inhibitors less effective if they are reserved for later lines of treatment.
Unlike other PARP inhibitor trials that used a less effective second-line hormonal agent as a comparator, the TRITON 3 study tested Rucaparib against a physician's choice that was predominantly docetaxel chemotherapy. This robust design against a true standard of care makes its positive outcome more clinically significant.